8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
The company has reported total income of Rs. 604.02 crores during the period ended March 31, 2023
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
Subscribe To Our Newsletter & Stay Updated
